Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Substituted diaminopyrimidine compound and application thereof in preparation of antineoplastic drugs

A technology of diaminopyrimidine and compound, which is applied in the field of medicinal chemistry to achieve the effects of inhibiting growth, good pharmacokinetic properties and overcoming drug resistance

Active Publication Date: 2017-06-13
药谷(温州)科技发展有限公司
View PDF6 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are certain defects in the drugs currently under clinical research or on the market. For example, CO-1686 generally has symptoms of hyperglycemia three weeks after taking the drug. drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted diaminopyrimidine compound and application thereof in preparation of antineoplastic drugs
  • Substituted diaminopyrimidine compound and application thereof in preparation of antineoplastic drugs
  • Substituted diaminopyrimidine compound and application thereof in preparation of antineoplastic drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Nitrogen-(5-((5-bromo-4-((1-methylindol-6-yl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl Piperazin-1-yl)phenyl)acrylamide (compound 23)

[0038] N-(5-((5-bromo-4-((1-methyl-1H-indol-6-yl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methylpiperazin-1 -yl)phenyl)acrylamide

[0039] The synthetic route is as follows:

[0040]

[0041] Step 1: Nitrogen-(5-bromo-2-chloropyrimidin-4-yl)-1-methyl-1hydro-indole-6-amino (intermediate c)N-(5-bromo-2-chloropyrimidin- 4-yl)-1-methyl-1H-indol-6-amine

[0042]

[0043] 5-bromo-2,4-dichloropyrimidine (3.42g, 15mmol), 1-methyl-1-hydro-indole-6-amino (1.46g, 10mmol), DIPEA (N,N-diisopropyl Ethylamine, 0.1 mL) was dissolved in 20 mL of anhydrous DMF, and the reaction was started at -20°C on a low-temperature reactor, and the temperature was gradually raised to 0°C within 5 hours. After reacting for 7 hours, 200 mL of ice water was added, a large amount of solid precipitated out, filtered under reduced pressure, and dried t...

Embodiment 2

[0064] Nitrogen-(5-((4-((1hydro-indol-6-yl)amino)-5-bromopyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl ) (methyl) amino) phenyl) acrylamide (compound 25)

[0065]N-(5-((4-((1H-indol-6-yl)amino)-5-bromopyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)phenyl ) acrylamide

[0066]

[0067] The synthetic method is as embodiment 1

[0068] 1 H NMR (600MHz, DMSO-d 6 )δ(ppm): 11.027(s,1H,indole-H-1),10.129(s,1H,-NH-),9.132(s,1H,-NH-),8.510(s,1H,-NH- ),8.232(s,1H,Ar-H),8.232(s,1H,H-6),7.516(s,1H,Ar-H),7.470(d,J=8.4Hz,1H,Ar-H) ,7.414(d,J=9.0Hz,1H,Ar-H),7.309(t,J=3.0Hz,1H,indole-H-2),7.181(d,J=8.4Hz,1H,Ar-H) ,6.826(d,J=7.8Hz,1H,Ar-H),6.400(t,,J=2.4Hz,1H,indole-H-3),6.353(dd,J1=17.0Hz,J2=10.2 Hz, 1H, -C H =CH 2 ), 6.226 (d, J=16.8Hz, 1H, -CH=C H 2 ),5.950(d,J=12.0Hz,1H,-CH=C H 2 ),2.720(t,J=7.2Hz,2H,-C H 2 -CH 2 -N(CH 3 ) 2 ),2.569(s,3H,N-CH 3 ), 2.207(t, J=7.2Hz, 2H, -CH 2 -C H 2 -N(CH 3 ) 2 ),2.171(s,6H,-N(C H 3 ) 2 ). 13 C NMR(150MHz,DMS...

Embodiment 3

[0070] Nitrogen-(5-((4-((1-hydrogen-indol-6-yl)amino)-5-bromopyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl ) phenyl) acrylamide (compound 20)

[0071] N-(5-((4-((1H-indol-6-yl)amino)-5-bromopyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acrylamide

[0072] The synthetic method is as embodiment 1

[0073]

[0074] 1 H NMR (600MHz, DMSO-d 6 )δ(ppm):11.054(s,1H,indole-H-1),9.150(s,1H,-NH-),8.954(s,1H),8.532(s,1H,-NH-),8.137( s,1H,H-6),7.984(s,1H,-NH-),7.533(s,1H,Ar-H),7.502(d,J=8.4Hz,1H,Ar-H),7.478(d ,J=9.0Hz,1H,Ar-H),7.329(t,J=2.4Hz,1H,indole-H-2),7.169(d,J=8.4Hz,1H),6.689(d,J=5.4 Hz,1H,Ar-H),6.571(dd,J 1=17.0Hz,J 2=10.2Hz,1H,-C H =CH 2 ), 6.432(t, J=2.4Hz, 1H, indole-H-3), 6.209(d, J=17.4Hz, 1H, -CH=C H 2 ), 5.734 (d, J=10.2Hz, 1H, -CH=C H 2 ), 2.694(t, J=4.8Hz, 4H, piperazine-H×4), 2.510(t, J=4.8Hz, 4H, piperazine-H×4), 2.246(s, 3H, N-CH 3 ). 13 CNMR(150MHz,DMSO)δ162.83,158.27,157.28,156.89,137.34,136.50,135.80,132.31,132.23,131.81,126.37,125.33,125.0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a substituted diaminopyrimidine compound and medicinal salt thereof. The structure of the substituted diaminopyrimidine compound is as shown in a general formula (I). A pharmacodynamic test proves that the compound is capable of effectively inhibiting growth of multiple tumor cells and can be used for preparing anti-tumor drugs, and meanwhile, the drug resistance of EGFR T790M can be overcome.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and specifically relates to a substituted diaminopyrimidine compound, its preparation method and its medical application, especially the application in the preparation of anti-malignant tumor drugs. Background technique [0002] Molecular targeted therapy is a method of selectively killing tumor cells by chemical or biological means, which has the characteristics of high selectivity, strong specificity, and mild side effects. This strategy has been developed rapidly in several years, and it is the hot spot and trend of tumor treatment at present. [0003] Malignant tumors, especially lung cancer, are the malignant tumors with the highest morbidity and mortality. According to the latest statistics, the number of new lung cancer patients in my country reached 733,000 in 2015, and the total number of deaths due to lung cancer reached about 610,000 within a year, accounting for the first of all ca...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D403/12C07D237/20C07D401/12A61K31/506A61K31/5377A61P35/00A61P35/02
CPCC07D237/20C07D401/12C07D403/12
Inventor 刘志国王怡蔡跃飘夏钦钦胡杰陈凌锋梁广
Owner 药谷(温州)科技发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com